Ryota Shiraki

This inventor holds 12 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Astellas Pharma Gmbh, Kotobuki Pharmaceutical Co Ltd, Yamanouchi Pharmaceutical Company Ltd.. Active years: 2003-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ryota Shiraki. Retrieved from https://idiyas.com/inventor/ryota-shiraki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 33.3

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 7.7

ph-index = 5

Forward Citations = 171(Granted Patents)

Location History:

Tsukuba, JP (2003 - 2012)
Chuo-ku, JP (2010 - 2012)
Tokyo, JP (2007 - 2017)

Company Filing History:

Kotobuki Pharmaceutical Co Ltd

patents

2 out of 329

Yamanouchi Pharmaceutical Company Ltd.

patents

4. 1 out of 2

Kotobuki Pharmaceuticals Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2003-2017

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9708307 - Heterocyclic acetamide compound (2017-07-18),

2. 8937087 - Heterocyclic acetamide compound (2015-01-20),

3. RE43481 - Diazepan derivatives or salts thereof (2012-06-18),

4. 8198464 - Method for producing C-glycoside derivative and intermediate for synthesis thereof (2012-06-12),

5. 8097592 - Cocrystal of C-glycoside derivative and L-proline (2012-01-17),

6. 7977466 - C-glycoside derivatives and salts thereof (2011-07-12),

7. 7776897 - Triazole derivative or salt thereof (2010-08-17),

8. 7772407 - C-glycoside derivatives and salts thereof (2010-08-10),

9. 7307074 - Diazepan derivatives or salts thereof (2007-12-11),

10. 7202350 - C-glycoside derivatives and salts thereof (2007-04-10),

11. 6740662 - Naphthyridine derivatives (2004-05-25),

12. 6642224 - Diazepan derivatives or salts thereof (2003-11-04),

Title: Ryota Shiraki: Innovator in Pharmaceutical Chemistry

Introduction

Ryota Shiraki is a prominent inventor based in Tokyo, Japan, known for his significant contributions to pharmaceutical chemistry. With a total of 12 patents to his name, he has made remarkable strides in the development of compounds that target neurological disorders.

Latest Patents

One of his latest patents involves a heterocyclic acetamide compound, which serves as a dopamine D1 receptor positive allosteric modulator (D1 PAM). This compound is particularly useful as an active ingredient in pharmaceutical compositions aimed at preventing and treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and various drug addictions. The research conducted by Shiraki and his team has led to the discovery that this heterocyclic acetamide compound possesses a dopamine D1 receptor positive allosteric modulating activity, thereby completing this innovative invention.

Career Highlights

Throughout his career, Ryota Shiraki has worked with notable companies in the pharmaceutical industry, including Astellas Pharma GmbH and Kotobuki Pharmaceutical Co. Ltd. His work has been instrumental in advancing the understanding and treatment of complex neurological conditions.

Collaborations

Shiraki has collaborated with esteemed colleagues such as Masakazu Imamura and Takeshi Murakami, contributing to the success of various research projects and patent applications.

Conclusion

Ryota Shiraki's innovative work in the field of pharmaceutical chemistry has led to significant advancements in the treatment of neurological disorders. His contributions continue to impact the industry positively, showcasing the importance of research and development in improving healthcare outcomes.

Profile summary based on public USPTO records.